Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system.

Published

Journal Article

Aim: To investigate the current state of TPMT testing at a single-academic medical center. Methods: Single-center, retrospective chart review for patients newly prescribed a thiopurine. Data collection and evaluation included the prevalence and timing of TPMT testing, correct dosage adjustment if applicable, and incidence of myelosuppression. Results: 121 patients (71%) received TPMT testing. Out of the tested patients, 110 (90.9%) were designated as wild-type with normal metabolism. Dosing modification was appropriate in applicable patients. In unadjusted analysis, there was a lower incidence of myelosuppression among patients who were tested versus those who were not (16.5 vs 36.7%). Conclusion: Based on the study results, TPMT testing opportunities exist for nearly 30% of patients. Testing may reduce the incidence of myelosuppression.

Full Text

Duke Authors

Cited Authors

  • Root, A; Johnson, R; McGee, A; Lee, H-J; Yang, S; Voora, D

Published Date

  • April 2020

Published In

Volume / Issue

  • 21 / 6

Start / End Page

  • 411 - 418

PubMed ID

  • 32308127

Pubmed Central ID

  • 32308127

Electronic International Standard Serial Number (EISSN)

  • 1744-8042

Digital Object Identifier (DOI)

  • 10.2217/pgs-2019-0148

Language

  • eng

Conference Location

  • England